# Dose-Escalation Study in Advanced Colon Cancer Patients

> **NCT00969046** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 60 (actual)

## Conditions studied

- Colon Cancer

## Interventions

- **DRUG:** EPO906 (patupilone)

## Key facts

- **NCT ID:** NCT00969046
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2006-11
- **Final completion:** 2006-11
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2020-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00969046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00969046, "Dose-Escalation Study in Advanced Colon Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00969046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*